Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Pluristem Therapeutics
Pluristem Therapeutics received approval from the Paul-Ehrlich-Institute, a German regulatory body, to expand its phase II clinical trial using PLX-PAD cells in patients suffering from Intermittent Claudication. Shares of the company spiked nearly 7 percent Tuesday.
Going forward ... (see research report)
Subscribe to News Feeds